drugset / Trial / NCT02950948

Progesterone in Luteal Phase Deficiency

NCT02950948

Phase 3 Withdrawn IBSA Institut Biochimique SA
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main objective of this study will be to assess the efficacy of natural progesterone at a daily dose of 25 mg in restoring a normal luteal phase. The primary end-point will be the ongoing pregnancy rate. The secondary objectives will be the rate of endometrial biopsy showing an in phase endometrium after 3 months of treatment. The length of the luteal phase of the menstrual cycle after treatment will also be assessed and compared with the initial duration (from LH peak to onset of menstruation).

Timeline

Start
2017-05-03
Primary completion
2019-03
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Progesterone Other / unclassified 25 mg Subcutaneous

Indications

No indication recorded.